ERBB2 and breast carcinoma: There, after the engagement of HER2-positive target cells, the intracellular CD147 domain was activated to trigger downstream signaling pathways to increase the production of MMPs, further induce infiltrations of T cells, and inhibit breast cancer growth in murine models.